Join
Live feed
·
PRReleasevia Quantisnow
Selecta Biosciences Inc. logo

Selecta Biosciences Announces Top Line Data from the Phase I SEL-399 AAV Empty Capsid Study, Highlighting Potential Benefits of ImmTOR™ in Gene Therapy

ByQuantisnow·Wall Street's wire, on your screen.
SELB· Selecta Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SELB (Selecta Biosciences Inc.) and more on Quantisnow.